Supplementary Fig. 9

A



B



C



Supplementary Figure 9. *Asf1a* KO and anti-PD-1 combination therapy primes and activates T cells that can recognize specific tumor-associated antigen. A, **B**, Re-challenge experiment shows the tumor formation capacity of MC38-Ctrl cells in MC38-Ctrl tumor-bearing mice or MC38-*Asf1a* KO tumor-bearing mice pretreated with PD-1 ab for 2 weeks. Re-challenged tumors were harvested 8 days after injection. Tumor images (**A**) and tumor volumes (**B**) from re-challenge experiments are shown. Ctrl + PD-1 ab, MC38-Ctrl tumor bearing mice pretreated with PD-1 ab; *Asf1a* KO + PD-1 ab, MC38-*Asf1a* KO tumor bearing mice pretreated with PD-1 ab. (Ctrl + PD-1 ab, n=3; *Asf1a* KO + PD-1 ab, n=4). **C**, *In vitro* tumor KP-Ctrl cell activity following co-culture with pan T cells isolated from spleens or lungs of KP-Ctrl plus vehicle pretreated mice or KP-*Asf1a* KO plus anti-PD-1 pretreated mice. Spleen, pan T cells isolated from spleens of KP-Ctrl tumor bearing mice; Ctrl, pan T cells isolated from lungs of KP-Ctrl tumor bearing mice pretreated with vehicle; *Asf1a* KO + PD-1 ab, pan T cells isolated from lungs of KP-*Asf1a* KO tumor bearing mice pretreated with anti-PD-1. (Spleen, n=6; Ctrl, n=6; *Asf1a* KO + PD-1 ab, n=6). All data are mean ± SEM. **p* < 0.05, ****p* <0.001